Treat hypertension with precision.


Using a non-invasive cheek swab, Geneticure's patented pharmaco­genomic panel analyzes 17 genotypes in 11 genes to recommend the best hypertension treatment for your patient.

We're offering complimentary testing for providers to demonstrate the value of the technology. Register for your provider account and we'll coordinate testing at no cost.

Register now

Geneticure report
Photo of a lab technician

The right prescriptions with hypertension-specific pharmaco­genomics.

Our CLIA-certified lab genotypes your patient's DNA from a cheek swab. Then, our patented algorithm uses years of research to predict which treatments will most effectively treat your patient's hypertension. We compile our findings into a personalized, one-page report.

Geneticure test kit

Reducing cost and improving care.

40% reduction in strokes.§ Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study. Eli F. Kelley, Eric M. Snyder, Nimer Alkhatib, Scott C. Snyder, Ryan Sprissler, Thomas P. Olson, Monica Akre, and Ivo Abraham. Journal of Medical Economics. 2018. Oct 22:1-8. DOI: 10.1080/13696998.2018.1531011. (PMID: 30280614)
25% reduction in heart attacks.§ Use of Blood Pressure Lowering Drugs in the Prevention of Cardiovascular Disease: Meta-analysis of 147 Randomized Trials in the Context of Expectations from Prospective Epidemiological Studies. MR Law, JK Morris, NJ Wald. BMJ 2009;338:b1665.
50% increased likelihood of meeting SPRINT guidelines.§ Association Between a Genetic Algorithm to Predict Hypertension Therapy and Response to Treatment. Clinicaltrials.gov identifier: NCT03292900. Completed.
47% decreased healthcare costs.§ Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study. Eli F. Kelley, Eric M. Snyder, Nimer Alkhatib, Scott C. Snyder, Ryan Sprissler, Thomas P. Olson, Monica Akre, and Ivo Abraham. Journal of Medical Economics. 2018. Oct 22:1-8. DOI: 10.1080/13696998.2018.1531011. (PMID: 30280614)
19% decreased event risk among diagnosed and controlled population.§ Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study. Eli F. Kelley, Eric M. Snyder, Nimer Alkhatib, Scott C. Snyder, Ryan Sprissler, Thomas P. Olson, Monica Akre, and Ivo Abraham. Journal of Medical Economics. 2018. Oct 22:1-8. DOI: 10.1080/13696998.2018.1531011. (PMID: 30280614)
50% decreased time to control patient's hypertension.§ Time to Blood Pressure Control According to Drug Class in Patients with Hypertension. MW Johnson, R Sprissler, TP Olson, GW Beenken, and EM Snyder. Presented at the American Society for Health-System Pharmacists, 2016. The FASEB Journal, 30(1) 941.12.

An evidence-first approach to personalized medicine.

Geneticure goes well beyond drug metabolism. Developed by scientific leaders in their fields, Geneticure's test assesses hypertension treatment in a comprehensive integrative nature, from drug metabolizing enzymes to receptors that are important to heart, blood vessel, and kidney function, with a focus on and appreciation of the complexity of the disease.

As seen in:

Peer-Reviewed Manuscripts
Presentations at National and International Meetings
Completed and Ongoing Trials
Cited Research

Other initiatives:

Get started with Geneticure

Geneticure is offering complimentary testing for providers to demonstrate the value of the technology.
Register here for your provider account (NPI# required) and we will coordinate testing at no cost.